Know Cancer

or
forgot password

A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma


Phase 4
18 Years
70 Years
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma


Inclusion Criteria:



1. Histologically confirmed localised prostate biopsy specimen that contains sufficient
tumour for evaluation of cell proliferation and apoptosis markers

2. Patients who are scheduled for radical prostatectomy with curative intents

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Proliferation by Ki67,

Principal Investigator

Teuvo L Tammela, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

Tampere University Central Hospital

Authority:

Finland: Finnish Medicines Agency

Study ID:

D6876C00001

NCT ID:

NCT00293696

Start Date:

October 2004

Completion Date:

November 2006

Related Keywords:

  • Prostate Cancer
  • biomarker study
  • Patients with clinically localised prostate cancer
  • Prostatic Neoplasms

Name

Location